Aktie A2ASAJ Q BIOMED INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Q BioMed Inc.

Aktien

A2ASAJ

US74736N1054

QBIO

Verzögert OTC Markets
Andere Börsenplätze
 15:46:06 10.05.2024 		% 5 Tage % 1. Jan.
0,000001 USD -99,83 % Intraday Chart für Q BioMed Inc. 0,00 % -50,00 %
2023 Q BioMed Inc. meldet Ergebnis für das erste Quartal bis zum 28. Februar 2023 CI
2023 Q BioMed Inc. meldet Ergebnis für das am 30. November 2022 beendete Geschäftsjahr CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Q BioMed Inc. Provides Update to Shareholders
Q BioMed Inc. Reports Earnings Results for the First Quarter Ended February 28, 2023
Q BioMed Inc. Reports Earnings Results for the Full Year Ended November 30, 2022
Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Patent from United States Patent Office and Notice of Allowance for Europe
Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Patent from United States Patent Office and Notice of Allowance for Europe
Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Notice of Allowance for Patent from United States Patent Office
Q BioMed Inc. Chemotherapeutic Uttroside B, Receives Notice of Allowance for Patent from United States Patent Office
Q BioMed Inc.'s Chemotherapeutic Uttroside B Receives Notice of Allowance for Patent from United States Patent Office
Q BIOMED INC. : Unregistered Sale of Equity Securities, Material Modification to Rights of Security Holders, Amendments to Articles of Inc. or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits (form 8-K)
Q BIOMED INC. Management's Discussion and Analysis of Financial Condition and Results of Operation (form 10-Q)
Q BioMed Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended August 31, 2022
Q BIOMED PROVIDES SHAREHOLDER UPDATE
Q BIOMED ANNOUNCES ISSUANCE OF PATENT FOR GROUNDBREAKING GDF15 BIOMARKER
Q BioMed Inc. Announces Issuance of Patent for Groundbreaking Gdf15 Biomarker
Q BioMed Inc. Provides Update to Shareholders
Q BioMed Inc. Reports Second Quarter Revenues in 2022
Q BioMed : Quarterly Report for Quarter Ending May 31, 2022 (Form 10-Q)
Q BIOMED INC. Management's Discussion and Analysis of Financial Condition and Results of Operation (form 10-Q)
Q BioMed Inc. Reports Earnings Results for the Second Quarter and Six Months Ended May 31, 2022
Q BioMed announces publication of pre-clinical research showing superior safety and efficacy against current first line therapy of its drug candidate Uttroside-B for liver cancer
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A2ASAJ Aktie
  4. Nachrichten Q BioMed Inc.
  5. Andere Sprachen